Endothelial ADAM10 controls cellular response to oxLDL and its deficiency exacerbates atherosclerosis with intraplaque hemorrhage and neovascularization in mice.
LOX-1
a disintegrin and metalloproteinase 10
atherosclerosis
endothelial cells
inflammatory signaling
intraplaque hemorrhage
neovascularization
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
06
2022
accepted:
13
01
2023
entrez:
13
2
2023
pubmed:
14
2
2023
medline:
14
2
2023
Statut:
epublish
Résumé
The transmembrane protease A Disintegrin And Metalloproteinase 10 (ADAM10) displays a "pattern regulatory function," by cleaving a range of membrane-bound proteins. In endothelium, it regulates barrier function, leukocyte recruitment and angiogenesis. Previously, we showed that ADAM10 is expressed in human atherosclerotic plaques and associated with neovascularization. In this study, we aimed to determine the causal relevance of endothelial ADAM10 in murine atherosclerosis development Endothelial Collectively, these results demonstrate that endothelial ADAM10 is atheroprotective, most likely by limiting oxLDL-induced inflammation besides its known role in pathological neovascularization. Our findings create novel opportunities to develop therapeutics targeting atherosclerotic plaque progression and stability, but at the same time warrant caution when considering to use ADAM10 inhibitors for therapy in other diseases.
Identifiants
pubmed: 36776254
doi: 10.3389/fcvm.2023.974918
pmc: PMC9911417
doi:
Types de publication
Journal Article
Langues
eng
Pagination
974918Informations de copyright
Copyright © 2023 van der Vorst, Maas, Theodorou, Peters, Jin, Rademakers, Gijbels, Rousch, Jansen, Weber, Lehrke, Lebherz, Yildiz, Ludwig, Bentzon, Biessen and Donners.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):249-56
pubmed: 23241413
Circulation. 1996 Feb 15;93(4):672-82
pubmed: 8640995
Circ Res. 2013 Jul 19;113(3):252-65
pubmed: 23748430
N Engl J Med. 2003 Dec 11;349(24):2316-25
pubmed: 14668457
Nat Commun. 2016 Jun 24;7:11853
pubmed: 27340017
Circ Res. 2016 Aug 5;119(4):519-31
pubmed: 27354212
Circulation. 2014 Jun 17;129(24):2557-66
pubmed: 24934463
J Biol Chem. 2009 Nov 6;284(45):31018-27
pubmed: 19726682
Methods Mol Biol. 2019;1930:99-113
pubmed: 30610604
Atherosclerosis. 1999 Mar;143(1):15-25
pubmed: 10208477
Circ Res. 2008 May 23;102(10):1192-201
pubmed: 18420943
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
J Cell Biol. 2015 Apr 13;209(1):13-22
pubmed: 25869663
Int J Oral Sci. 2021 Nov 15;13(1):36
pubmed: 34782601
Cells. 2021 Jan 25;10(2):
pubmed: 33504031
Atherosclerosis. 2012 Oct;224(2):302-8
pubmed: 22698791
Atherosclerosis. 2009 Jan;202(1):176-82
pubmed: 18514661
Cardiovasc Res. 1997 May;34(2):255-65
pubmed: 9205537
J Thromb Haemost. 2006 Jun;4(6):1186-93
pubmed: 16706957
Circ Res. 2014 May 23;114(11):1684-9
pubmed: 24677271
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Blood. 2011 Jul 28;118(4):1163-74
pubmed: 21652679
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Circ Res. 2016 Jul 22;119(3):450-62
pubmed: 27245171
Eur J Cell Biol. 2012 Jun-Jul;91(6-7):472-85
pubmed: 22138087
Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2188-95
pubmed: 20814017
Dev Dyn. 2010 Oct;239(10):2594-602
pubmed: 20803506
Mediators Inflamm. 2017;2017:9621724
pubmed: 28260841
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Eur J Pharmacol. 2017 Dec 5;816:3-13
pubmed: 28483459
Am J Pathol. 2015 Apr;185(4):1145-55
pubmed: 25659879
Thromb Haemost. 2018 Jul;118(7):1167-1175
pubmed: 29874690
Hypertension. 2005 Sep;46(3):622-7
pubmed: 16116044
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Front Cardiovasc Med. 2021 Jan 20;7:594441
pubmed: 33553253
Hum Mol Genet. 2002 Oct 1;11(21):2615-24
pubmed: 12354787
Thromb Haemost. 2017 Feb 28;117(3):644-646
pubmed: 28004058
J Neurosci. 2010 Apr 7;30(14):4833-44
pubmed: 20371803
J Exp Med. 2019 Apr 1;216(4):807-830
pubmed: 30819724
Circulation. 2011 Nov 8;124(19):2129-38
pubmed: 21986280
Sci Rep. 2017 Sep 15;7(1):11670
pubmed: 28916789
Nature. 2007 Feb 15;445(7129):776-80
pubmed: 17259973
Circulation. 2007 May 15;115(19):2516-25
pubmed: 17470698
Acta Pathol Jpn. 1987 Apr;37(4):627-37
pubmed: 3113173
Eur Heart J. 2015 May 1;36(17):1049-58
pubmed: 24553721
Basic Res Cardiol. 1996 Mar-Apr;91(2):111-22
pubmed: 8740527
Vascul Pharmacol. 2018 Feb;101:38-47
pubmed: 29174013
Angiogenesis. 2015 Jan;18(1):13-22
pubmed: 25218057